Key facts, as of
As of October 8, 2026, DexCom Inc. (DXCM) trades at $84.30, up 27.7% over the past year. Its 52-week range runs from $54.11 to $92.59; the price is 9.0% below that high. It is 48.9% below its all-time high of $164.86, reached in November 2021. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +293.7%, against +312.9% for the S&P 500 (SPY). It sits 15.0% above its 200-day average of $73.33, the usual sign of a long-term uptrend. Its 30-day volatility is 23.0% annualized, which we rate medium risk. It has a trailing P/E of 33.5.
Cite: Portfolio Terminal, "DexCom Inc. (DXCM) stock analysis", 2026-10-08. https://portfolio-terminal.com/analyse/dxcm
Where it trades today
trading 78% of the way up its 52-week range
How the price has moved
How far it is from its record
DexCom Inc. (DXCM) is 48.9% below its all-time high of $164.86, reached in November 2021. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +293.7%, against +312.9% for the S&P 500 (SPY).
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- DXCM trades at 33.5x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- DXCM carries a beta of 1.48, which means the stock should be judged on how it affects total portfolio swings, not just on standalone upside.
- Relative performance versus UNH, JNJ, PFE matters here because leadership inside healthcare rarely stays static for long.
Portfolio Use Case
- DXCM is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- This name works better as a satellite or higher-conviction growth position because it can amplify market swings in both directions.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in DXCM.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
- There is little income cushion here, so total return depends mainly on price appreciation and execution staying on track.
Methodology
- Price, market cap, beta, yield, and liquidity fields for DXCM come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for DXCM. Last refresh: Oct 8, 2026, 10:10 AM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What DexCom Inc. does
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and…
What analysts expect
DXCM carries a strong buy consensus from 26 analysts, with an average price target of $96.23 versus $84.30 today (+14.2%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
DXCM generated $4.97B in trailing revenue (13.1% year over year), with a 20.1% net margin, and $1.02B of free cash flow, supported by $548.60M of net cash.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $4.66B | $2.80B | $911.80M | $836.30M | $2.14 | $1.08B |
| 2024 | $4.03B | $2.44B | $600.00M | $576.20M | $1.46 | $630.70M |
| 2023 | $3.62B | $2.29B | $597.70M | $541.50M | $1.40 | $511.90M |
| 2022 | $2.91B | $1.88B | $391.20M | $341.20M | $0.88 | $304.70M |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
DXCM is in 8 of the 30 ETFs we track. It weighs most in XLV: 0.53% of the fund, holding #37 of 62.
Famous investors who hold it
DXCM is in the latest 13F of 2 of the 15 famous investors we follow. Renaissance Technologies (Founded by Jim Simons) holds the most of it: 0.15% of the portfolio, position #139 of 2,931, as of Q2 2026.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
DXCM beside the healthcare names it is usually measured against.
What the chart is saying
Slipped under its 50-day average inside a longer uptrend.
weakening- Price is 3.2% below its 50-day average and 15.0% above its 200-day.
- The 50-day crossed above the 200-day on 2026-06-29 (a “golden cross”).
- RSI at 43 is neither stretched nor washed out.
- The nearest ceiling is $92.46 (+9.7%), the nearest floor $79.03 (-6.3%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is DXCM a good investment in 2026?
DexCom Inc. trades at a P/E ratio of 33.5, with medium volatility (23.0% annualized). The stock is in a consolidation phase.
What is the risk level of DXCM?
Based on 30-day volatility of 23.0%, DXCM has MEDIUM risk. Beta of 1.48 indicates higher sensitivity to market movements than average.
Does DXCM pay dividends?
DexCom Inc. currently does not pay a regular dividend.
How far is DXCM from its all-time high?
DexCom Inc. is 48.9% below its all-time high of $164.86, reached in November 2021. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +293.7%, against +312.9% for the S&P 500 (SPY).
Which ETFs hold DXCM?
8 of the 30 popular ETFs we track hold DexCom Inc.. The largest weights: XLV (0.53%), QQQ (0.14%), QQQM (0.14%), VUG (0.12%) and VOO (0.05%). Measured on each issuer's full holdings file, dated August 31 to October 1, 2026.
How much of VOO is DXCM?
0.05%, as of August 31, 2026: DXCM is holding #284 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $0.53 in DexCom Inc..
Which famous investors own DXCM?
Renaissance Technologies (0.15% of Founded by Jim Simons's 13F) and Ray Dalio (0.11% of Bridgewater Associates's 13F), according to their latest Form 13F filings with the SEC (Q2 2026). A 13F lists US long positions 45 days after the quarter ends, so it can be out of date.
What is the analyst price target for DXCM?
The average analyst price target for DexCom Inc. (DXCM) is $96.23 based on 26 analyst estimates, about 14.2% above the current price of $84.30. The published range runs from $79.00 to $115.00.
How much revenue does DXCM generate?
DexCom Inc. reported $4.97B in trailing twelve-month revenue. Revenue growth is running at 13.1% year over year. Net margin sits at 20.1%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare DXCM with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.